Avantor

AVTR

Market cap $8.66B

Overview Fund Activity

12.71 USD

+0.32

2.58%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

12.71

0.00

0%

1 day

2.58%

5 days

-0.08%

1 month

-0.39%

3 months

-5.36%

6 months

-23.02%

Year to date

-40.05%

1 year

-53.27%

5 years

-44.18%

10 years

-12.34%

About: Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.

Employees: 13,500

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

86% more funds holding in top 10

Funds holding in top 10: 7 [Q1] → 13 (+6) [Q2]

58% more call options, than puts

Call options by funds: $43.6M | Put options by funds: $27.7M

53% more repeat investments, than reductions

Existing positions increased: 214 | Existing positions reduced: 140

43% more first-time investments, than exits

New positions opened: 93 | Existing positions closed: 65

4.45% more ownership

Funds ownership: 100.39% [Q1] → 104.84% (+4.45%) [Q2]

4% more funds holding

Funds holding: 476 [Q1] → 496 (+20) [Q2]

14% less capital invested

Capital invested by funds: $11.1B [Q1] → $9.62B (-$1.53B) [Q2]

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

6% downside

Avg. target

$14.33

13% upside

High target

$17

34% upside

9 analyst ratings

7 positive

78%

2 neutral

22%

0 negative

0%

Stifel Daniel Arias	$12	Hold Maintained	4 Aug 2025
JP Morgan Rachel Vatnsdal	$14	Overweight Maintained	4 Aug 2025
Evercore ISI Group Vijay Kumar	$16	Outperform Maintained	4 Aug 2025
Morgan Stanley Tejas Savant	$12	Equal-Weight Maintained	4 Aug 2025
Barclays Luke Sergott	$13	Overweight Maintained	4 Aug 2025
Wells Fargo Brandon Couillard	$16	Overweight Maintained	4 Aug 2025
RBC Capital Conor McNamara	$17	Outperform Maintained	4 Aug 2025
Raymond James Andrew Cooper	$14	Outperform Reiterated	4 Aug 2025
Baird Catherine Schulte	$15	Outperform Maintained	4 Aug 2025

See Analyst Rankings

Financial journalist opinion

Engine Capital takes a stake in Avantor. Activist sees several ways to create value

Engine believes that Avantor's significant underperformance is a consequence of self-inflicted mistakes rooted in a flawed leadership team and framework.

Engine Capital takes a stake in Avantor. Activist sees several ways to create value

Investors Business Daily

Avantor Surges As Activist Investor Takes Aim At 'Self-Inflicted' Issues

Avantor surged Monday as Engine Capital digs in to reverse what the activist investor says are years of "extreme" value destruction.

Avantor Surges As Activist Investor Takes Aim At 'Self-Inflicted' Issues

Avantor® Reiterates Shareholder Value Creation Focus

Emmanuel Ligner, Seasoned Leader with Proven Track Record of Value Creation in Life Sciences, to Begin Role as CEO Next Week RADNOR, Pa. , Aug. 11, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today issued the following statement in response to the letter issued by Engine Capital: The Board of Directors is actively engaged in overseeing the setting and execution of the Company's strategy and is committed to always acting in the best interests of the Company and its shareholders.

Avantor® Reiterates Shareholder Value Creation Focus

Activist investor Engine Capital urges Avantor to refresh board with new directors

Activist investor Engine Capital has urged medical equipment maker Avantor to refresh its board with new directors, a letter on Monday showed.

Activist investor Engine Capital urges Avantor to refresh board with new directors

Engine Capital Sends Letter to Avantor's Board of Directors Regarding Opportunities to Improve Governance and Unlock Shareholder Value

NEW YORK--(BUSINESS WIRE)--Engine Capital LP (together with its affiliates, “Engine” or “we”), which owns approximately 3% of the outstanding shares of Avantor, Inc. (NYSE: AVTR) (“Avantor” or the “Company”), today sent a letter to the Company's Board of Directors outlining several opportunities to close Avantor's significant valuation gap and unlock value for shareholders. The letter can be viewed and downloaded here. About Engine Capital Engine Capital LP is a value-oriented special situation.

Engine Capital Sends Letter to Avantor's Board of Directors Regarding Opportunities to Improve Governance and Unlock Shareholder Value

Engine Capital builds stake in Avantor, plans to push it to sell itself, WSJ reports

Activist investor Engine Capital has built a stake in Avantor and plans to push the life-sciences company to sell itself or make other changes, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

Engine Capital builds stake in Avantor, plans to push it to sell itself, WSJ reports

Activist Investor to Push Avantor to Sell Itself

Engine Capital has a roughly 3% stake in the life-sciences company.

Activist Investor to Push Avantor to Sell Itself

The Motley Fool

Avantor Q2 Revenue Tops Estimates

Avantor Q2 Revenue Tops Estimates

Avantor Q2 Revenue Tops Estimates

Zacks Investment Research

AVTR Stock Declines as Q2 Earnings Miss Estimates, Revenues Down Y/Y

Avantor stock dips more than 15% as Q2 EPS missed estimates, revenue declines year over year and lowers full-year guidance.

AVTR Stock Declines as Q2 Earnings Miss Estimates, Revenues Down Y/Y

Avantor Q2 Feels The Impact From Bioprocessing Shortfalls, Customer Headwinds, Continued Margin Pressure

Avantor Inc. AVTR stock is trading lower on Friday after the company reported worse-than-expected second-quarter 2025 adjusted EPS.

Avantor Q2 Feels The Impact From Bioprocessing Shortfalls, Customer Headwinds, Continued Margin Pressure

See News Rankings

Charts implemented using Lightweight Charts™